Broker’s call: ICICI Pru Life (Buy)

Target: ₹670

Target: ₹670

CMP: ₹590

ICICI Prudential Life Insurance Co. Ltd. (IPRU), a joint venture between ICICI Bank and Prudential Corp. Holdings, offers life, health and pension products.

Also read:Broker’s call: TVS Motor (Reduce)In Q4FY24, net premium income rose 17.1 per cent y-o-y to ₹14,788 crore, driven by robust growth in non-par life insurance, annuity non-par, and linked life. The annualised premium equivalent (APE) grew 9.5 per cent y-o-y in Q4-FY24, underpinned by a strong distribution network and digital support.

Value of New Business (VNB) declined 19.5 per cent y-o-y to ₹2,227 crore in FY24, and the VNB margin weakened to 24.6 per cent from 32 per cent in FY23. In the future, IPRU management aims to maintain the growing absolute VNB margin, as the effect of commission guidelines has already been factored in. A better product mix and strong customer demand should support VNB margin.

IPRU witnessed better business growth as a result of increased premium income and APE in Q4FY24. The company’s continuous focus on strengthening its distribution network, product and process innovation, and digitalisation in business processes, is expected to boost future performance and provide a sustainable outlook on the stock.

Therefore, we retain our BUY rating on the stock, with a target price of ₹670 based on 1.7x FY26E EV

Like (0)
Previous May 10, 2024 10:28 pm
Next May 10, 2024 10:28 pm

Related posts

  • Guangxin Shares (603599.SH): Net profit in the first quarter was 225 million yuan, a year-on-year decrease of 56.80%

    Gelonghui April 25 | Guangxin Co., Ltd. (603599.SH) released its first quarter report for 2024. During the reporting period, the company’s operating income was 1.215 billion yuan, a year-on-year decrease of 36.89%; the net profit attributable to shareholders of the listed company was 225 million yuan, A year-on-year decrease of 56.80%; the net profit attributable to shareholders of listed companies excluding non-recurring gains and losses was 215 million yuan, a year-on-year decrease of 55.06%; basic earnings per share was 0.25 yuan/share.

    US stock market April 25, 2024
  • Must-read before U.S. stocks open: Three major stock index futures rise, TSMC falls more than 2%

    As of press time, the Dow futures, dominated by blue-chip stocks, rose 0.24%; the S&P 500 futures rose 0.25%; the Nasdaq 100 futures, dominated by technology stocks, rose 0.29%. Popular Chinese concept stocks rose before the market opened. European stock markets rose. As of press time, Germany’s DAX index fell 0.08%; France’s CAC40 index rose 0.39%; Britain’s FTSE 100 index rose 0.14%. In terms of commodity foreign exchange, as of press time, Brent crude oil fell 1.10% to US$86.33 per barrel. European Automobile Manufacturers Association: EU car sales hit biggest decline in 16 months in March The European Automobile Manufacturers Association said that EU car sales suffered the largest decline in 16 months in March, and Tesla‘s new car registrations in the EU fell by 30% in March. Registrations of pure electric vehicles in the EU fell by 11% to 134,400 in March; the EU’s pure electric vehicle market share fell to 13% from 14% in the same period last year. Swiss gold exports fell 6.9% month-on-month in March Swiss gold exports fell 6.9% month-on-month in March. TSMC’s Q1 net…

    US stock market April 18, 2024
  • Nordisk fell 1.1% in premarket as the U.S. Senate launches investigation into Novo Nordisk\’s GLP-1 drug pricing

    Gelonghui, April 25 | Nord Nordisk (NVO.US) U.S. stocks fell 1.1% before the market opened, to US$124.74. On the news, U.S. Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders said on Wednesday that the committee is launching an investigation into Novo Nordisk\’s pricing. In a letter sent to Novo Nordisk\’s CEO on Wednesday, Sanders asked Novo Nordisk to provide \”internal communications about the U.S. pricing of the drug\” and explain why Ozempic and Wegovy have the same ingredient (semaglutide). ), Wegovy’s pricing is obviously more expensive. Sanders stressed that the price of GLP-1 drugs \”must come down\” so that consumers can afford them and the government doesn\’t go bankrupt by reimbursing them.

    US stock market April 25, 2024
  • Dongfeng Technology: Net profit in the first quarter of 2024 was 14.6946 million yuan, a year-on-year increase of 37.76%

    Dongfeng Technology (600081) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 1.573 billion yuan, a year-on-year increase of 5.01%; net profit attributable to the parent company was 14.6946 million yuan, a year-on-year increase of 37.76%; non-net profit after deduction was 2.0046 million yuan, a year-on-year decrease of 72.69%; Net cash flow was 69.9454 million yuan, a year-on-year decrease of 50.28%; during the reporting period, Dongfeng Technology\’s basic earnings per share was 0.0254 yuan, and the weighted average return on net assets was 0.32%.

    US stock market April 25, 2024
  • Hedge fund Rokos executive: Fed unlikely to cut interest rates this year

    Richard Tang, global head of markets at hedge fund Rokos Capital Management, believes the Fed is unlikely to loosen monetary policy this year.

    US stock market May 16, 2024
  • The weakening of interest rate cut expectations caused shocks, and European commercial real estate sales fell to a 13-year low.

    In recent years, Europe\’s commercial real estate industry has been hit by sharp rises in debt costs and sharp falls in house prices. Especially after the epidemic, some office buildings and commercial areas have become inaccessible, and the situation has become increasingly severe.

    US stock market April 25, 2024